76838-72-7

Upstream product

• 108-86-1 bromobenzene 
• 20734-76-3 2-amino-4-methoxyphenol 
• 1568-70-3 4-methoxy-2-nitrophenol 
• 100-67-4 potassium phenolate 
• 5344-78-5 4-bromo-3-nitroanizole 
• 108-95-2 phenol 
• 10298-80-3 2-chloro-5-methoxynitrobenzene 
• 84594-95-6 5-methoxy-1-nitro-2-phenoxybenzene 

Downstream Products

• 76838-71-6 1-Benzoyl-3-(5-methoxy-2-phenoxy-phenyl)-thiourea 
• 102077-92-9 4',5-Dimethoxy-2-phenoxy-diphenyl-ether 
• 1655-69-2 1-methoxy-4-phenoxy-benzene 
• 37950-44-0 5-Methoxi-4-nitro-2-phenoxi-trifluormethansulfonanilid 
• 76841-08-2 Imidazolidin-2-ylidene-(5-methoxy-2-phenoxy-phenyl)-amine 
• 76838-93-2 (5-Methoxy-2-phenoxy-phenyl)-thiourea 
• 149436-41-9 α-amino-2-methoxy-4-methanesulfonamido-5-phenoxyacetophenone hydrochloride 
• 123664-55-1 ethyl 2-(2-benzyloxy-4-methylsulfonylamino-5-phenoxybenzoyl)acetate 
• 123664-56-2 ethyl 3-[2-hydroxy-4-[(methylsulfonyl)amino]-5-phenoxyphenyl]-3-oxopropanoate 
• 123663-68-3 ethyl 7-[(methylsulfonyl)amino]-4-oxo-6-phenoxy-4H-3-chromenecarboxylate 
• 123664-66-4 7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one-2-carboxylic acid azide 

Relevant academic research and scientific papers

Preparation method of 4 -phenoxyl -3 -aminoanisole

The invention discloses a preparation method of 4 - phenoxyl -3 -aminoanisole, which comprises the following steps: adding 4 - phenoxyl -3 - nitroanisole, a solvent to an autoclave, adding 0.5 - 5% molecular sieve loaded 2.5% nickel as a catalyst, and rep

COMPOUNDS COMPRISING N-METHYL-2-PYRIDONE, AND PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention concerns compounds comprising N-methyl-2-pyridone, and pharmaceutically-acceptable salts and compositions of such compounds. Such compounds are useful in anti-inflammatory and anti-cancer therapies. Therefore, the present invention also concerns such compounds for use as medicaments, particularly for the treatment of inflammatory diseases and oncology.

Iguratimod intermediate and synthesis method thereof

The invention belongs to the technical field of chemical drug synthesis, and particularly relates to an Iguratimod key intermediate and a synthesis method thereof. The synthesis method comprises the following steps: carrying out reduction on 4-methoxy-2-n

Synthesis and antiinflammatory activity of 7-methanesulfonylamino-6- phenoxychromones. Antiarthritic effect of the 3-formylamino compound (T-614) in chronic inflammatory disease models

A group of derivatives of 7-methanesulfonylamino-6-phenoxychromone (1) at the pyrone and phenoxy rings was synthesized starting with 4-chloro-3- nitroanisole and evaluated against acute and chronic inflammations in oral administration in animals. Significant potency in the rat models of carrageenin-induced edema (CPE) and adjuvant-induced arthritis (AA) was realized with 2'-fluoro and 2',4'-difluoro derivatives (9a and 9d), and 3- formylamino derivative (19a) and its 2'-fluoro and 2',4'-difluoro compounds (22a and 22d), displaying AA therapeutic effect of ED40=2.5-7.1 mg/kg/d for 7 d and AA prophylactic effect of 53-70% inhibition at the dosage of 3 mg/kg/d for 22 d. To identify a candidate for further pharmacological study, the five compounds were subjected to evaluation of their gastro-ulcerogenic liability, leading to selection of the fluorine-free compound 19a which did not cause acute ulceration at 300 mg/kg in oral administration in rats. Compound 19a (ED40=3.6 mg/kg in established AA) possessed good therapeutic efficacy against type II collagen-induced arthritis in DBA/1J mice with doses of 30 and 100 mg/kg, suggesting the development of 19a (designated T-614) as a prospective disease-modifying antirheumatic agent. In addition, a preparative-scale synthetic route to T-614 has been established.

1-,2-,3-,4-,5-,6-,7-,8- AND/OR 9 SUBSTITUTED DIBENZOXAZEPINE COMPOUDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING PAIN

The present invention provides substituted dibenzoxazepine compounds of Formula I: STR1 which are useful as analgesic agents for the treatment of pain, pharmaceutical compositions comprising a therapeutically-effective amount of a compound of Formula I in combination with a pharmaceutically-acceptable carrier, and a method for eliminating or ameliorating pain in an animal comprising administering a therapeutically-effective amount of a compound of Formula I to the animal.

4H-1-benzopyran-4-one derivative or its salt, process for producing the same and pharmaceutical composition comprising the same as active ingredient

This invention relates to a 4H-1-benzopyran-4-one derivative represented by the formula: STR1 or a salt thereof, a process for producing the same and a pharmaceutical composition comprising the same as active ingredient.